Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  VBI Vaccines Inc.    VBIV   CA91822J1030

VBI VACCINES INC.

(VBIV)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/18/2020 05/19/2020 05/20/2020 05/21/2020 05/22/2020 Date
2.17(c) 2.5(c) 2.49(c) 2.455(c) 2.46(c) Last
13 706 693 26 374 202 27 828 565 13 376 174 5 071 065 Volume
+14.81% +15.21% -0.40% -1.41% +0.20% Change
More quotes
Financials (USD)
Sales 2020 2,64 M - -
Net income 2020 -44,4 M - -
Net Debt 2020 - - -
P/E ratio 2020 -12,0x
Yield 2020 -
Sales 2021 13,5 M - -
Net income 2021 -39,6 M - -
Net Debt 2021 - - -
P/E ratio 2021 -14,7x
Yield 2021 -
Capitalization 567 M 567 M -
Capi. / Sales 2020 215x
Capi. / Sales 2021 41,9x
Nbr of Employees -
Free-Float 70,0%
More Financials
Company
VBI Vaccines Inc. is a development-stage biotechnology company. The Company's principal products include cytomegalovirus (CMV) Vaccine Candidate, enveloped Virus Like Particle (eVLP) Vaccine Platform and Lipid Particle Vaccine (LPV) Vaccine Platform. The Company is also engaged in the research and development (R and D) activity. The Company's subsidiaries includes Variation Biotechnologies (US), Inc. (VBI US) and... 
Sector
Biotechnology & Medical Research
Calendar
06/18 | 01:00pmShareholder meeting
More about the company
Surperformance© ratings of VBI Vaccines Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on VBI VACCINES INC.
05/21VBI-2901 : Pan-Coronavirus Vaccine Candidate Overview
PU
05/15VBI VACCINES : Announces Upcoming Poster Presentation of Phase 1/2a data of VBI-..
BU
05/15Hedge Funds Expect a Cure But Are Wary of Betting Big -- WSJ
DJ
05/14Correction to Coronavirus Cure Investing Article
DJ
05/14Why Big Investors Aren't Betting It All on a Coronavirus Cure -- 2nd Update
DJ
05/14Why Big Investors Aren't Betting It All on a Coronavirus Cure -- Update
DJ
05/14Why Big Investors Aren't Betting It All on a Coronavirus Cure
DJ
05/06VBI VACCINES : Announces First Quarter 2020 Financial Results and Provides Corpo..
PU
05/06VBI VACCINES : Announces First Quarter 2020 Financial Results and Provides Corpo..
BU
04/27VBI VACCINES : Announces Closing of Public Offering of Common Stock and Full Exe..
BU
04/22VBI VACCINES : Announces Pricing of $50 Million Public Offering
BU
04/21VBI VACCINES : Announces Proposed Public Offering of Common Shares
BU
03/31VBI VACCINES : Announces Collaboration with the National Research Council of Can..
BU
03/12VBI VACCINES : Appoints Damian Braga to Board of Directors
BU
03/05VBI VACCINES : Provides Corporate Update, Outlook for 2020, and Year-End 2019 Fi..
BU
More news
News in other languages on VBI VACCINES INC.
2019VBI VACCINES : annonce la phase 2a de l'évaluation clinique du candidat-vaccin V..
2019VBI VACCINES : veröffentlicht klinische Evaluierung der Phase 2a des Krebsimpfst..
More news
Chart VBI VACCINES INC.
Duration : Period :
VBI Vaccines Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VBI VACCINES INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 3,75 $
Last Close Price 2,46 $
Spread / Highest target 103%
Spread / Average Target 52,4%
Spread / Lowest Target 22,0%
EPS Revisions
Managers
NameTitle
Jeffrey R. Baxter President, Chief Executive Officer & Director
Steven H. Gillis Chairman
Christopher McNulty CFO, Director & Head-Business Development
David Evander Anderson Chief Scientific Officer
Francisco Diaz-Mitoma Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
VBI VACCINES INC.78.26%567
LONZA GROUP36.64%36 889
IQVIA HOLDINGS INC.-7.51%27 289
SEATTLE GENETICS, INC.36.33%26 964
MODERNA, INC.252.76%26 829
CELLTRION, INC.18.78%23 248